Women's Health · ContraceptionRegulatory Approvalcompetitivemid-term

Lupin's ANDA091440 for Levonorgestrel and Ethinyl Estradiol Receives AP Status

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Lupin4 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/23/2026, 12:32:03 PM

Assessment confidence: 68% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

Lupin's receipt of Abbreviated Approval for Levonorgestrel and Ethinyl Estradiol signifies a new competitive entrant in the contraceptive market. This development necessitates a strategic reassessment by existing players to maintain market share and respond effectively to Lupin's market strategies. Regulatory context from FDA (FDA AP — LEVONORGESTREL AND ETHINYL ESTRADIOL (SUPPL)) supports the near-term read. Assessment grounded in 30 ranked evidence items (16 high-relevance).

Strategic Assessment

Portfolio teams should evaluate the competitive landscape for contraceptive products and consider strategic positioning against Lupin's entry. The strongest clinical anchor is Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel) (ClinicalTrials.gov), entity match (levonorgestrel). In Women's Health · Contraception, 8 regulatory and 7 competitive items passed relevance filtering for Lupin.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from [Ad hoc announcement pursuant to Art.. This approval positions Lupin to compete in the contraceptive market, potentially impacting existing players with similar products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — LEVONORGESTREL AND ETHINYL ESTRADIOL (SUPPL) (FDA). Entity match (lupin); Regulatory pathway relevance (nda). The Abbreviated Approval status indicates compliance with regulatory standards, but ongoing monitoring of Lupin's launch and market performance is essential to anticipate any regulatory challenges.

Key Risks

Elevated medium regulatory exposure for Lupin could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Lupin's entry could disrupt market dynamics, potentially affecting revenue streams for established contraceptive products and altering competitive positioning.
Portfolio teams should evaluate the competitive landscape for contraceptive products and consider strategic positioning against Lupin's entry.

What Would Change This Assessment

This becomes more urgent if Monitor Lupin's launch timeline and market uptake of ANDA091440, as well as responses from competitors.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — LEVONORGESTREL AND ETHINYL ESTRADIOL (SUPPL)
FDAhigh relevance
Entity match (lupin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL (SUPPL)
FDAhigh relevance
Entity match (levonorgestrel); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TWIRLA (SUPPL)
FDAhigh relevance
Entity match (levonorgestrel); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ESTRADIOL (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ESTRADIOL AND NORETHINDRONE ACETATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ESTRADIOL (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ESTRADIOL AND NORETHINDRONE ACETATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — NDA219627
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source

Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
ClinicalTrials.govhigh relevance
Entity match (levonorgestrel)
FDA document
View source
A Study to Learn if Medicine Called Itraconazole Changes How the Body Processes the Study Medicine PF-08642534 in Healthy Adults.
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Controls and Healthy Vasculature Initiative
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy of INTOFINE-JOINT SUPPORT DIETARY SUPPLEMENT on Bone and Joint Health
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Host and Parasite Factors That Influence Susceptibility to Malaria Infection and Disease During Pregnancy and Early Childhood in Ouelessebougou and Bamako, Mali
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improvement of Quality of Life in Stage III-IV Melanoma Patients
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Cooking Health-Oriented Meals to Prevent Dementia and Diabetes
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants
Humanexa Signalshigh relevance
Sponsor/company relevance (Merck)
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)

Progestin therapy in premenopausal women with incidental meningioma-a narrative review and recommendations for women's health specialists.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Significance of GSH and H(2)S regulation for cancer: an intricate interplay between diet, microbiota, metabolic reprogramming, and immune health.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Burden of HPV-associated cancers in Peruvian men: Evidence from national health data.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Safety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
' they just take one pill, so it is easy to use, more convenient ': South African health care provider perspectives on Dual Prevention Pill.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Recent advances in the relationship between mental symptoms in postmenopausal women and estrogen fluctuations.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Factors predicting health-enhancing physical activity in patients with chronic widespread pain following a person-centred health plan.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Lupin
Levonorgestrel

Commercial impact

medium

Lupin's entry could disrupt market dynamics, potentially affecting revenue streams for established contraceptive products and altering competitive positioning.

Regulatory impact

medium

The Abbreviated Approval status indicates compliance with regulatory standards, but ongoing monitoring of Lupin's launch and market performance is essential to anticipate any regulatory challenges.

What to watch

Monitor Lupin's launch timeline and market uptake of ANDA091440, as well as responses from competitors.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.